Advertisement

Hereditary Risk for Cancer

Chapter
  • 1.6k Downloads

Abstract

Cancer prevention consists of understanding cancer incidence in populations, identifying appropriate risk factors for specific cancers, stratifying individuals according to these risk factors, and applying effective interventions to individuals (and sometimes populations) according to their risk status. Evaluation of hereditary risk of cancer is a vital component of risk stratification. Appropriate assessment of hereditary genetic risk can lead to significant changes in the clinical management of individuals who are found to have a hereditary cancer syndrome; conversely, it can identify individuals who are not at elevated risk despite having a strong familial history of cancer. Through cancer risk evaluation, with or without genetic testing for hereditary cancer syndromes, individuals with inherited genetic changes associated with increased predisposition of cancer can be identified prior to the development or diagnosis of cancer. Determining that an individual has a strong inherited predisposition to cancer provides an opportunity to intervene with prevention and screening strategies documented to reduce cancer incidence, morbidity, or mortality.

Keywords

Breast Cancer Ovarian Cancer Genetic Counseling Endometrial Cancer Familial Adenomatous Polyposis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91(15):1310–1316Google Scholar
  2. Aarnio M, Sankila R et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218PubMedCrossRefGoogle Scholar
  3. ACOG (1997) ACOG committee opinion. Breast–ovarian cancer screening. Number 176, October 1996. Committee on Genetics. The American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 56(1):82–83CrossRefGoogle Scholar
  4. Ad Hoc Committee on Genetic Counseling (1975) Genetic counseling. Am J Hum Genet 27(2):240–242Google Scholar
  5. Amos C, Frazier M, McGarrity T (2007) Peutz-Jeghers syndrome. In: GeneReviews. www.genetests.org, University of Washington. Accessed 27 Mar 2008
  6. Aretz S et al (2005) High proportion of large genomic STK11 deletions in Peutz Jegers syndrome. Hum Mutat 26:513–519PubMedCrossRefGoogle Scholar
  7. ASCO (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397–2406CrossRefGoogle Scholar
  8. ASHG (1994) Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55(5):i–ivGoogle Scholar
  9. Baker LH (1982) Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin 32(4):194–225PubMedCrossRefGoogle Scholar
  10. Bane AL, Beck JC, Bleiweiss I et al (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31:121–128PubMedCrossRefGoogle Scholar
  11. Barnes-Kedar IM, Plon SE (2002) Counseling the at risk patient in the BRCA1 and BRCA2 era. Obstet Gynecol Clin North Am 29(2):341–366, viiPubMedCrossRefGoogle Scholar
  12. Boardman LA, Thibodeau SN et al (1998) Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 128(11):896–899PubMedCrossRefGoogle Scholar
  13. Brooks-Wilson AR et al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41:508–517PubMedCrossRefGoogle Scholar
  14. Brownstein MH, Wolf M et al (1978) Cowden’s disease: a cutaneous marker of breast cancer. Cancer 41(6):2393–2398PubMedCrossRefGoogle Scholar
  15. Burke W, Daly M et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277(12):997–1003PubMedCrossRefGoogle Scholar
  16. Burn J, Gerdes AM et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized clinical trial. Lancet 378:2081–2087PubMedCrossRefGoogle Scholar
  17. Burt RW et al (2013) NCCN Clinical practice guidelines in oncology (NCCN Guidelines (R))colorectal cancer creening version 2.2013. © national comprehensive cancer network, Inc. Available at www.nccn.org. Accessed 30 Sep 2013
  18. Chompret A, Abel A et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43–47PubMedCrossRefGoogle Scholar
  19. Claus EB, Risch N et al (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73(3):643–651PubMedCrossRefGoogle Scholar
  20. Couch FJ, Weber BL et al (1996) Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mutat 8(1):8–18PubMedCrossRefGoogle Scholar
  21. Daly MB et al (2013) NCCN clinical practice guidelines in oncology (NCCN guidelines (R)) Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 4.2013. © 2013 National Comprehensive Cancer Network, Inc. Available at www.nccn.org. Accessed 30 Sep 2013
  22. Domchek SM, Eisen A et al (2003) Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 21(4):593–601PubMedCrossRefGoogle Scholar
  23. Dunlop MG, Farrington SM et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105–110PubMedCrossRefGoogle Scholar
  24. EGAPP Working Group (2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35–41CrossRefGoogle Scholar
  25. Eisen A, Lubinski J et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Nat Cancer Inst 100:1361–1367PubMedCrossRefGoogle Scholar
  26. Eng C (2000) Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37(11):828–830PubMedCrossRefGoogle Scholar
  27. Fackenthal JD, Marsh DJ et al (2001) Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38(3):159–164PubMedCrossRefGoogle Scholar
  28. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767PubMedCrossRefGoogle Scholar
  29. Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662PubMedCrossRefGoogle Scholar
  30. Ford D, Easton DF et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343(8899):692–695PubMedCrossRefGoogle Scholar
  31. Frank TS, Manley SA et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417–2425PubMedGoogle Scholar
  32. Franks LM, Teich NM (1997) Introduction to the cellular and molecular biology of cancer. Oxford University Press, LondonGoogle Scholar
  33. Geller G, Botkin JR et al (1997) Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA 277(18):1467–1474PubMedCrossRefGoogle Scholar
  34. Giardiello FM, Brensinger JD et al (1997) The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 336(12):823–827PubMedCrossRefGoogle Scholar
  35. Goss PE, Ingle JN et al (2011) Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391PubMedCrossRefGoogle Scholar
  36. Hall JM, Lee MK et al (1990) Linkage of early-onset familial breast cancer to chromosome-17q21. Science 250(4988):1684–1689PubMedCrossRefGoogle Scholar
  37. Hampel H, Peltomaki P (2000) Hereditary colorectal cancer: risk assessment and management. Clin Genet 58(2):89–97PubMedCrossRefGoogle Scholar
  38. Hartmann LC, Sellers TA et al (1999) Clinical options for women at high risk for breast cancer. Surg Clin North Am 79(5):1189–1206PubMedCrossRefGoogle Scholar
  39. Hemminki A (1999) The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 55(5):735–750PubMedCrossRefGoogle Scholar
  40. Hemminki A, Markie D et al (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391(6663):184–187PubMedCrossRefGoogle Scholar
  41. Izatt L, Greenman J et al (1999) Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer 26(4):286–294PubMedCrossRefGoogle Scholar
  42. Jenkins MA et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population based case–family study. Cancer Epidemiol Biomarkers Prev 15(2):312–314PubMedCrossRefGoogle Scholar
  43. Johannesdottir G, Gudmundsson J et al (1996) High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56(16):3663–3665PubMedGoogle Scholar
  44. Kempers MJ, Kuiper RP et al (2011) Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 12:49–55PubMedCrossRefGoogle Scholar
  45. King JE, Dozois RR et al (2000) Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 75(1):57–67PubMedCrossRefGoogle Scholar
  46. King MC et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP–P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedCrossRefGoogle Scholar
  47. King MC, Marks JH et al (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646PubMedCrossRefGoogle Scholar
  48. Knudson AG (1971) Mutation and cancer – statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823PubMedCrossRefGoogle Scholar
  49. Kohlman W, Gruber SB (2004) Hereditary non-polyposis colon cancer. In: GeneReviews. www.genetests.org. Accessed 10 Nov 2004
  50. Kriege M, Brekelmans CT et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437PubMedCrossRefGoogle Scholar
  51. Lerman C, Hughes C et al (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31(1):75–80PubMedCrossRefGoogle Scholar
  52. Li FP, Fraumeni JF Jr et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362PubMedGoogle Scholar
  53. Liede A, Karlan BY et al (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742PubMedCrossRefGoogle Scholar
  54. Lynch HT, Lynch JF (1998) Genetics of colonic cancer. Digestion 59(5):481–492PubMedCrossRefGoogle Scholar
  55. Lynch HT, Lynch JF (2000) Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 18(4):305–313PubMedCrossRefGoogle Scholar
  56. Madalinska JBM et al (2007) Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 25:301–307PubMedCrossRefGoogle Scholar
  57. Malander S, Ridderheim M et al (2004) One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 40(3):422–428PubMedCrossRefGoogle Scholar
  58. Meijers-Heijboer H et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59PubMedCrossRefGoogle Scholar
  59. Miki Y, Swensen J et al (1994) Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene. Science 266:61–71CrossRefGoogle Scholar
  60. Narod SA, Risch H et al (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339(7):424–428PubMedCrossRefGoogle Scholar
  61. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. J Natl Compr Canc Netw 2011;9:1238–1290Google Scholar
  62. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. J Natl Compr Canc Netw 2010;8:562–594Google Scholar
  63. NCI (1998) Breast cancer risk assessment tool for health care providers. N. C. I. Office of Cancer Communication, BethesdaGoogle Scholar
  64. NCI (2007) Breast cancer risk assessment tool. http://bcra.nci.nih.gov/brc/. Accessed 10 Mar 2008
  65. Nelen MR, Padberg GW et al (1996) Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 13(1):114–116PubMedCrossRefGoogle Scholar
  66. Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence for review for the US Preventive Services Task Force. Ann Intern Med 143:362–379PubMedCrossRefGoogle Scholar
  67. NSGC (2004) National Society of Genetic Counselors home page. www.nsgc.org. Accessed 10 Nov 2004
  68. Nussbaum RL, McInnes RR, Willard HF (2001) Thompson and Thompson genetics in medicine. W.B. Saunders Company, PhiladelphiaGoogle Scholar
  69. Offit K (1997) Clinical cancer genetics: risk counseling and management. Wiley-Liss, New YorkGoogle Scholar
  70. Parmigiani G, Wang W (2004) BRCAPRO. B. Lab, http://astor.som.jhmi.edu/BayesMendel/brcapro.html. Accessed 10 Nov 2004
  71. Parmigiani G, Berry D et al (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRefGoogle Scholar
  72. Peelen T, vanVliet M et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60(5):1041–1049PubMedGoogle Scholar
  73. Peelen T, de Leeuw W et al (2000) Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis. Int J Cancer 88(5):778–782PubMedCrossRefGoogle Scholar
  74. Peltomaki P, Vasen HF (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113(4):1146–1158PubMedCrossRefGoogle Scholar
  75. Pennington KP, Swisher EM (2012) Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 124(2):347–353PubMedCrossRefGoogle Scholar
  76. Peters JA, Stopfer JE (1996) Role of the genetic counselor in familial cancer. Oncology (Huntingt) 10(2):159–166Google Scholar
  77. Petrij-Bosch A, Peelen T et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17(3):341–345PubMedCrossRefGoogle Scholar
  78. Rebbeck TR, Friebel T et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062PubMedCrossRefGoogle Scholar
  79. Rebbeck TR, Friebel T et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 carriers: the PROSE Study Group. J Clin Oncol 23(31):7804–7810PubMedCrossRefGoogle Scholar
  80. Risch HA, McLaughlin JR et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700–710PubMedCrossRefGoogle Scholar
  81. Rumilla K, Schowalter KV et al (2011) Frequency of deletions of EPCAM (TACSTD1) in MSH2 associated Lynch syndrome. J Mol Diagn 13:93–99PubMedCrossRefGoogle Scholar
  82. Savitsky K, Sfez S et al (1995) The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4(11):2025–2032PubMedCrossRefGoogle Scholar
  83. Schmidt MK et al (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 25:64–69PubMedCrossRefGoogle Scholar
  84. Schneider K (2001) Counseling about cancer: strategies for genetic counseling. Wiley-Liss, New YorkGoogle Scholar
  85. Schrag D, Kuntz KM et al (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336(20):1465–1471PubMedCrossRefGoogle Scholar
  86. Shattuck-Eidens D, Oliphant A et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242–1250PubMedCrossRefGoogle Scholar
  87. Smith A et al (2007) Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 44:10–15PubMedCrossRefGoogle Scholar
  88. Solomon C, Burt RW (2004) Familial adenomatous polyposis. In: GeneReviews. www.genetests.org, University of Washington. Accessed 2 Apr 2004
  89. Struewing JP, Hartge P et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408PubMedCrossRefGoogle Scholar
  90. Swift M, Morrell D et al (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325(26):1831–1836PubMedCrossRefGoogle Scholar
  91. Thompson D, Easton D et al (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68(2):410–419PubMedCrossRefGoogle Scholar
  92. Thull DL, Vogel VG (2004) Recognition and management of hereditary breast cancer syndromes. Oncologist 9(1):13–24PubMedCrossRefGoogle Scholar
  93. Tinat J, Bouregard G et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27:e108–e109PubMedCrossRefGoogle Scholar
  94. Tirkkonen M, Johannsson O et al (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57(7):1222–1227PubMedGoogle Scholar
  95. Tonin P, Weber B et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2(11):1179–1183PubMedCrossRefGoogle Scholar
  96. Tonin PN et al (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63(5):1341–1351PubMedCrossRefGoogle Scholar
  97. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846–5853PubMedCrossRefGoogle Scholar
  98. Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRefGoogle Scholar
  99. Umar A, Boland CR et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRefGoogle Scholar
  100. Vasen HF, van Ballegooijen M et al (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82(9):1632–1637PubMedCrossRefGoogle Scholar
  101. Vogel VG, Costantino JP et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741PubMedCrossRefGoogle Scholar
  102. Walsh T et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388PubMedCrossRefGoogle Scholar
  103. Warner E, Plewes DB et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317–1325PubMedCrossRefGoogle Scholar
  104. Watanabe T, Wu TT et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344(16):1196–1206PubMedCrossRefGoogle Scholar
  105. Weber T (1996) Clinical surveillance recommendations adopted for HNPCC. Lancet 348:465CrossRefGoogle Scholar
  106. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG (2007) Increased risk of breast cancer associated with CHEK2*1100delC germline mutation. J Clin Oncol 25:64–69Google Scholar
  107. Wijnen JT, Vasen HF et al (1998) Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339(8):511–518PubMedCrossRefGoogle Scholar
  108. Wooster R, Bignell G et al (1995) Identification of the breast-cancer susceptibility gene BRCA2. Nature 378(6559):789–792PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Hematology-OncologyMayo Clinic-ScottsdaleScottsdaleUSA
  2. 2.Department of Medicine, Division of Hematology-OncologyUniversity of Arizona Cancer CenterTucsonUSA

Personalised recommendations